Gregory D. Gorgas, Chief Executive Officer of Artelo, added, “ART12.11 was purpose-built to meet the standards required for federal healthcare integration and prescription-based use, and we believe it ...

LEXINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Hydra Biosciences, Inc. today announced plans to begin a Phase 1 clinical trial for a small ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Learn more about whether BioMarin Pharmaceutical Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Friday, December 26, 2025. Let’s ...

NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on ...

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed ...

CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies ...

MONTPELLIER, France, November 12, 2025--(BUSINESS WIRE)--Regulatory News: NFL Biosciences SA (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical ...

Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios Zimberelimab ...

BF Biosciences Limited, a Pakistani pharmaceutical company, has announced a change at the top, with founding Chief Executive Officer (CEO) Akhter Khalid Waheed set to step down on December 31, 2025, ...

LITTLETON, Colo. and CHICAGO, June 3, 2025 /PRNewswire/ -- DeFloria, Inc., the botanical-drug developer advancing the first of its kind AJA001 oral solution for autism spectrum disorder (ASD), today ...